公开(公告)号：US20230053603A1

公开(公告)日：2023-02-23

申请号：US17805331

申请日：2022-06-03

申请人： ADC THERAPEUTICS SA ,  MEDIMMUNE LIMITED

发明人： Patricius Hendrikus Cornelis VAN BERKEL

IPC分类号： C07D519/00 ,  A61K47/68

摘要： The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.

公开(公告)号：US20220403048A1

公开(公告)日：2022-12-22

申请号：US17637052

申请日：2020-08-21

申请人： Cancer Research Technology Limited ,  Medimmune Limited

发明人： Alexandra Addyman ,  Mark Austin ,  Michelle Barnard ,  Vincenzo Cerundolo ,  Denice Chan ,  Agata Diamandakis ,  Sebastian Fielder ,  Maria Groves ,  Stuart Haynes ,  Sarah Holt ,  Lesley Jenkinson ,  Stephanie Keswick ,  Fiona McLaughlin ,  Pooja Sharma ,  Yoko Shibata ,  Louise Slater ,  Jessica Whitehouse ,  Mark D Carr ,  Daniel Burschowsky ,  Chitra Seewooruthun

IPC分类号： C07K16/40 ,  C12N9/78 ,  A61P43/00

摘要： An isolated antigen-binding protein characterised in that it is capable of binding specifically to human Arginase II (ARG2) and inhibiting the enzyme activity of human ARG2.

公开(公告)号：US20220363748A1

公开(公告)日：2022-11-17

申请号：US17755604

申请日：2020-11-03

申请人： MedImmune Limited

发明人： David James BAKER ,  Carol Patricia MORENO QUINN ,  Kevin James WOOLLARD ,  Asha SETH ,  Elena LIARTE MARIN ,  Barbara MUSIAL ,  Emma Suzanne COHEN ,  Sam STRICKSON ,  Kirsty HOUSLAY

IPC分类号： C07K16/24 ,  C07K16/28

摘要： present disclosure relates to a method of treating kidney injury, by administering an anti-IL-33 therapeutic agent which inhibits both ST2 signaling and RAGE signaling.

公开(公告)号：US20220347309A1

公开(公告)日：2022-11-03

申请号：US17414622

申请日：2019-12-18

申请人： ADC THERAPEUTICS SA ,  MEDIMMUNE LIMITED

发明人： John Hartley

IPC分类号： A61K47/68 ,  A61K31/5517 ,  C07K16/28 ,  A61P35/00 ,  C12Q1/6886

摘要： The present disclosure relates to methods of determining if a proliferative disorder such as cancer is resistant to treatment with a pyrrolobenzodiazepine (PBD) agent, such as a therapeutic antibody-drug conjugate (ADC) comprising a PBD warhead conjugated to an antibody (PBD-ADC). The present disclosure also describes methods of selecting subjects suitable for treatment with a PBD agent, and methods of reducing the resistance of a proliferative disorder to a PBD agent.

公开(公告)号：US11479539B2

公开(公告)日：2022-10-25

申请号：US16955403

申请日：2018-12-20

申请人： MedImmune Limited

发明人： Johan Bartholomeus ,  Roland Bürli ,  Rebecca Jarvis ,  Shawn Johnstone ,  Thor Ostenfeld ,  Ina Terstiege ,  Massimiliano Travagli ,  Stephane Turcotte

IPC分类号： C07D401/04 ,  C07D213/61 ,  C07D417/04

摘要： The present application relates to compounds of formula (I′) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

公开(公告)号：US20220306754A1

公开(公告)日：2022-09-29

申请号：US17697041

申请日：2022-03-17

申请人： MedImmune Limited

发明人： Josquin NYS ,  Albert THOM ,  Peter CARIUK ,  Darren SCHOFIELD ,  Aidan RILEY ,  Catherine HUNTINGTON ,  David REES ,  Lorraine IRVING ,  Matthew ROBINSON

IPC分类号： C07K16/28 ,  A61P1/00

摘要： The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.

公开(公告)号：US11426467B2

公开(公告)日：2022-08-30

申请号：US16622663

申请日：2018-06-14

申请人： ADC THERAPEUTICS SA ,  MEDIMMUNE LIMITED

发明人： Jay Marshall Feingold ,  Jens Wuerthner

IPC分类号： A61K47/68 ,  A61K47/54 ,  A61P35/00 ,  A61K31/5517 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

摘要： The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS).

公开(公告)号：US20220249617A1

公开(公告)日：2022-08-11

申请号：US17612020

申请日：2020-05-20

申请人： MEDIMMUNE LIMITED

发明人： ANNE-LAURE LAINE ,  LUTZ JERMUTUS ,  ANA GOMES DOS SANTOS

IPC分类号： A61K38/26 ,  A61K31/724 ,  A61K31/7034 ,  A61K45/06

摘要： Provided herein are coformulations comprising cyclodextrin that allow for concurrent, subcutaneous administration of sodium glucose co-transporter 2 inhibitors (SGLT2i), such as dapagliflozin, and incretin peptides, such as GLP-1/Glucagon dual agonist peptides.

公开(公告)号：US20220195037A1

公开(公告)日：2022-06-23

申请号：US17540672

申请日：2021-12-02

申请人： MedImmune Limited

发明人： Elaine M. HURT ,  Ralph MINTER ,  Steven RUST ,  Alan SANDERCOCK ,  Sotirios KARATHANASIS

IPC分类号： C07K16/28 ,  C12N5/095 ,  G01N33/574 ,  C07K16/30 ,  C12Q1/25 ,  A61K31/713 ,  A61K31/704

摘要： The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.

公开(公告)号：US20220160881A1

公开(公告)日：2022-05-26

申请号：US17439639

申请日：2020-03-13

申请人： MEDIMMUNE LIMITED

发明人： Philip Wilson Howard ,  Thais Cailleau

IPC分类号： A61K47/55 ,  A61K47/54 ,  A61P35/00

摘要： A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.